Objective: Concerns about increased breast cancer risk with estrogen and progestin therapy have led to an increased interest in progestin alternatives. The main objective of this study was to determine if bazedoxifene acetate (BZA), a new selective estrogen receptor modulator, will antagonize the proliferative and transcriptional effects of conjugated equine estrogens (CEE) in the breast.
M enopause is associated with an increased risk of osteoporosis and a range of adverse symptoms that decrease the quality of life of postmenopausal women. 1 Traditional menopausal hormone therapy (HT) regimens including estrogen-alone therapy (ET) and estrogen + progestin therapy (EPT) are commonly used to treat these conditions, 2<4 but the effects of these therapies on the breast and endometrium have raised concerns about cancer risk.
Although the proliferative cancer-promoting actions of estrogens on the endometrium can be opposed by progestin cotherapy, 5, 6 results from the Women's Health Initiative clinical trials 7, 8 and several observational studies 9, 10 have associated long-term use of EPT with an increased risk of invasive breast cancer. Consequently, considerable recent research has been dedicated to finding an alternative to the progestin component of EPT that will act in a tissue-specific manner to allow treatment of menopausal-related conditions without increasing risk for breast and endometrial cancer.
Possible candidates for this role are selective estrogen receptor modulators (SERMs), which bind to estrogen receptors > (ER->) and A (ER-A) with high affinity and elicit either an estrogen agonistic or antagonistic transcriptional response depending on the target tissue. 11 Current SERMs do not relieve vasomotor and vaginal atrophy symptoms when administered alone, 12<14 leading to a new approach to menopausal HT in which a SERM is given in combination with one or more estrogens. 15 It has been proposed that this combination may provide a safe and therapeutic balance of tissueselective ER agonism and antagonism for postmenopausal women, including those at high risk for breast cancer. 16, 17 Ideally, the estrogens in this combination therapy will relieve vasomotor symptoms, improve vaginal maturation, and provide protective effects against bone loss and atherosclerosis progression, whereas the SERM will provide antiproliferative effects in the breast and endometrium.
Bazedoxifene acetate (BZA) is a newly developed SERM currently under regulatory review for the prevention and treatment of osteoporosis in postmenopausal women. In a 3-year study of osteoporotic postmenopausal women, BZA given alone significantly increased lumbar spine and hip bone mineral density, reduced bone turnover, and significantly decreased the risk of new vertebral fractures compared with placebo. 18 In addition, BZA given at 20 mg/day significantly reduced the risk of nonvertebral fractures in a subgroup of women at high risk for osteoporosis. 18 In a series of clinical trials (Selective estrogens, Menopause, And Response to Therapy [SMART]) investigating the efficacy and risk profile of several BZA and CEE dose regimens, BZA at 20 mg/day combined with CEE at 0.45 mg/day was the lowest effective dose regimen to prevent endometrial hyperplasia, relieve hot flushes, improve lipid profiles, and maintain bone mass in healthy postmenopausal women. 19<22 After 2 years of treatment, the first SMART trial (SMART-1) reported a low incidence of abnormal mammogram results (G5%) and breast cancer (G0.3%) with BZA 20 mg + CEE 0.45 mg among 3,397 postmenopausal women 23 ; however, further studies were needed to fully determine the risk profile of BZA + CEE in the breast.
The primary objective of this study was to investigate the breast profile of BZA alone and in combination with conjugated equine estrogens (CEE), the most widely prescribed ET in the United States. 24 We hypothesized that BZA will inhibit the proliferative and transcriptional effects of CEE on the breast epithelium, whereas BZA will lack estrogenic activity when administered alone. This report is the first in a series evaluating the effects of BZA with and without CEE on atherosclerosis progression, serum lipids, bone mineral density, vaginal maturation, and breast/endometrial proliferation in the context of a 20-month randomized, nonhuman primate preclinical trial. The data presented here include interim assessments on breast biopsies obtained after 6 months of treatment.
METHODS

Animal model and study design
The animal model for this study was the female cynomolgus macaque (Macaca fascicularis). The female human breast and macaque breast share many histological and physiological features that result in comparable tissue and transcriptional responses to exogenous sex hormones. 25 For these reasons, this model has been used in many previous studies to evaluate the hormone-associated risk profile of menopausal HTs and SERMs. 26<29 Other advantages of this model are the ability to perform repeat breast biopsies without sacrificing and to assess the effects of new HTs on multiple organ systems in the same subject in an effort to determine a global benefit to risk profile.
One hundred adult female cynomolgus macaques were imported from the Indonesian Primate Center (Pusat Studi Satwa Primata) at the Institut Pertanian Bogor in West Java, Indonesia. For this study population, the estimated mean age as determined by dentition was 12 years, with no differences between experimental groups. All animals were monoparous or multiparous based on clinical records from the original breeding colony. After quarantine, all animals were ovariectomized and randomized by body weight into social groups consisting of two to five animals. Social groups were then assigned to one of four experimental groups to receive no treatment (control, n = 23) or treatment with BZA 20 mg (n = 22) or CEE 0.45 mg (n = 25), or the combination of BZA 20 mg + CEE 0.45 mg (n = 25). Each experimental group originally consisted of 25 animals, but 2 animals from the control and 3 animals from the BZA groups were excluded because of elevated serum ovarian hormone concentrations postovariectomy, indicating the presence of ectopic ovarian tissue, a spontaneous condition previously reported in cynomolgus macaques. 30 Treatments were administered in the diet and given once daily for 20 months. As previously mentioned, interim measurements presented here came from breast biopsies taken after 6 months of treatment. Further assessments of BZA + CEE and BZA effects on the breast, uterus, vagina, bone, and the cardiovascular system after 20 months of treatment are ongoing and will be reported separately.
All procedures using these animals were approved by the Institutional Animal Care and Use Committee of Wake Forest University and were conducted in accordance with federal, state, and institutional guidelines. The facilities and animal resources program of Wake Forest University are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Diet and drug dose determinations
All monkeys were fed an isoflavone-free casein/lactalbuminbased cake diet prepared by the Wake Forest University Primate Center (WFUPC) diet laboratory and formulated to be equivalent in cholesterol, macronutrients (fat, protein, carbohydrates), and vitamin and mineral content. The amounts of macronutrients and supplemental cholesterol (0.29 mg/Cal) were formulated to model diets typically consumed by women in the United States. To account for differences in metabolic rates between monkeys and women, the standard clinical dose of CEE (0.45 mg/day) was scaled to 1,800 Cal of diet (the estimated daily intake of US women). All monkeys consumed approximately 120 Cal of diet per kilogram of body weight, providing approximately 0.03 mg/kg/day of CEE.
A pilot study was conducted to determine a BZA dose for monkeys that most closely resembled plasma concentrations measured in postmenopausal women receiving 20 mg/day. Target doses of 2.0 or 2.5 mg/kg were investigated based on information provided by a previous metabolic study using macaques given a single oral dose of BZA via gavage. 31 The pilot study conducted at the WFUPC was designed to determine the bioavailability and palatability of BZA when fed once daily in a high-fat cake diet for multiple days. Eight monkeys were fed cake diets containing either 2.0 or 2.5 mg/kg of BZA for 5 days. Blood was then collected at 0, 4, 24, 48, and 72 hours postprandial and analyzed by Pfizer using highperformance liquid chromatography with fluorescence detection. The area under the curve from time 0 to 24 hours of BZA was then calculated and compared with that of BZA measured in postmenopausal women receiving 20 mg/day from a similarly designed pharmacokinetic study. 32 As a result, the BZA dose of 2.5 mg/kg was selected and used for the reminder of the study. The metabolic disposition of BZA in monkeys has been reported previously to be similar to women. 31, 33 Estrogens and BZA measurement Serum hormone and drug concentrations, along with body weights, were measured to confirm adequate dosing and dietary intake among the treatment groups. Because estrone (E 1 ) is the major estrogen component of CEE, 34 E 1 levels were used as the primary indicator of equivalent estrogen exposure between the CEE and BZA + CEE treatment groups. Blood samples to measure E 1 , 17A-estradiol (E 2 ), and BZA concentrations were obtained at 4 hours postprandial and after an overnight fast (18-24 h) . Serum E 1 and E 2 concentrations were measured at the WFUPC Clinical Laboratory using commercially available radioimmunoassay kits (Siemens/DPC, Webster, TX). Serum obtained for E 2 concentrations was first extracted using ethyl ether, and extracts were then dried and reconstitued with zero-standard serum. For E 2 values below the lowest standard in the kit (2.5 pg/mL), a predetermined surrogate value of 2.49 pg/mL was used for statistical analyses. Plasma BZA concentrations were measured at Pfizer using high-performance liquid chromatography with fluorescence detection. For BZA values below the lowest standard (1.00 ng/mL), a predetermined surrogate value of 0.99 ng/mL was used for statistical analysis.
Breast biopsies
After 6 months of treatment, all monkeys were sedated with ketamine HCl (15 mg/kg) and atropine (0.03 mg/kg), intubated, surgically prepared, and maintained on isoflurane (1%-2%). A 2.0-cm incision was made, and 0.6 g of breast tissue from the upper lateral breast quadrant was removed, bisected, and prepared for histology and gene expression studies as previously described. 35 Adjacent tissue sections from each animal were used for histomorphometry and immunostaining.
Histomorphometry and histopathology
Fixed breast tissue sections were stained with hematoxylin and eosin and were digitized using an Infinity 3 digital camera (Lumenera, Lawrenceville, GA). As a surrogate marker for mammographic density in women, the total epithelial area (lobuloaveolar units and extralobular ducts) in each biopsy sample was quantified by histomorphometry using techniques previously described. 25 Hematoxylin and eosinYstained breast biopsy tissues were also evaluated qualitatively for morphological changes related to epithelial proliferation and exogenous estrogen exposure by a board-certified veterinary pathologist (C.E.W.). Lobular enlargement (a lobule containing 950 acini) is a physiological change in the breast seen after exogenous estrogen exposure. 36 Columnar cell change and hyperplasia with or without atypia are benign proliferative lesions in the breast and are potential risk markers for human breast cancer. 37, 38 All histomorphometry and histopathological evaluations were completed by persons blinded to the treatment groups.
Immunohistochemistry
Breast tissue sections were immunostained using commercially available primary monoclonal antibodies for the proliferation marker Ki67 (Ki67SP6; Thermo Scientific, Fremont, CA; 1:100 dilution) and the sex steroid receptors ER-> (NCL-ER-6F11; Novocastra Reagents, Leica Microsystems Inc., Buffalo, NY; 1:100 dilution) and progesterone receptor (NCL-PGR-312; Novocastra Reagents, Leica Microsystems Inc.; 1:100 dilution) using methods similar to those described elsewhere. 35 Nuclear immunolabeling was then quantified using a computer-assisted manual counting technique with a grid filter to select cells for counting (Image-Pro Plus software, Media Cybernetics, Silver Spring, MD). 25 The number of positively stained cells was expressed as a percentage of the total number examined (100 cells) for each breast epithelial structure (lobular, extralobular ductal, and terminal ductal epithelium). All immunohistochemistry (IHC) counting was performed by a technician blinded to the treatment groups.
Quantitative real-time polymerase chain reaction
Transcript levels for key genes associated with breast proliferation (MKI67, Ki67 antigen), ER activity (ESR1, ER->; ESR2, ER-A; PGR, progesterone receptor; TFF1, trefoil factor 1 [pS2]; and GREB1, gene regulated by estrogen in breast cancer 1), apoptosis (BCL-2, B-cell CLL/lymphoma 2), and estrogen metabolism (CYP19, aromatase; HSD17B1, 17-A hydroxysteroid dehydrogenase [HSD] type 1; HSD17B2, 17-A HSD type 2; STS, estrogen sulfatase; SULT1E1, sulfotransferase family 1E, estrogen-preferring, member 1) were measured using quantitative real-time reverse transcriptionYpolymerase chain reaction (qRT-PCR). All primer-probe sets for specific gene targets were generated through the ABI TaqMan service and validated by previous macaque studies in our laboratory. 29, 35, 36, 39 Standard curves were performed, revealing 95% to 99% efficiency for all assays. Both custom macaque and commercially available human assays were used. Total RNA was extracted from frozen samples of breast tissue using Tri Reagent (Molecular Research Center, Cincinnati, OH), purified using RNeasy Mini kits (QIAGEN, Valencia, CA), and quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop, Thermo Scientific). One animal in the control and one animal in the CEE group were excluded because of low RNA content. Group numbers for the remaining 93 samples available for gene expression studies were 22 for the control, 22 for the BZA, 24 for the CEE, and 25 for the BZA + CEE groups. RNA aliquots (5 Hg per sample) were then reverse transcribed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA). qRT-PCR reactions (10 HL volume) were performed on an Applied Biosystems 7500 Fast Real-Time PCR System using standard TaqMan reagents and thermocycling protocol. A-Actin was used as the endogenous control, whereas reference breast tissue cDNA was run in parallel for plate-to-plate calibration. Relative expression of each target gene was calculated using ABI Relative Quantification 7500 Software v2.0.1.
Gene microarrays
Four samples of total RNA from each treatment group (n = 16) were selected randomly and submitted to Beckman Coulter Genomics (formerly Cogenics, Morrisville, NC) for gene microarray assays. RNA integrity was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.), and only samples with an RNA integrity number greater than 6.0 were used to generate biotin-labeled cRNA. Biotinylated cRNA from each sample was hybridized to an Affymetrix GeneChip Rhesus Macaque Genome Array. 29 
Statistical analyses
All variables were evaluated for their distribution and equality of variance. Data not normally distributed were transformed (log10 or square root) to improve the normality for analysis and then were reverse transformed to the original scale for display in the results. Histomorphometry, IHC for ER-> and Ki67, and all qRT-PCR data except for MKI67 and TFF1 had equality of variance; therefore, these data were assessed using analysis of variance (ANOVA). If a significant overall treatment effect was detected, then the Tukey honestly significant difference post hoc test was used for multiple pairwise comparisons. The IHC data for PGR and the relative gene expression of TFF1 and MKI67 violated the Levene test for equality of variance; therefore, these data were analyzed using the nonparametric Kruskal-Wallis and the post hoc Wilcoxon (rank sums) tests. P values were then adjusted for multiple pairwise comparisons using a Bonferroni correction (four comparisons, each treatment group vs control and CEE vs BZA + CEE). Body weights among the treatment groups were compared using a mixed-model approach with baseline body weight as a covariate. This model allowed for the comparison of baseline and 6-month posttreatment body weights within each treatment as well as the comparison of body weights among the treatment groups within the baseline and 6-month posttreatment time periods. A similar mixed-model approach was used to determine E 1 , E 2 , and BZA concentrations at 4 and 18 to 24 hours postprandial, except baseline measures, as covariates were not necessary in these models. A two-tailed Fisher's exact test was used to evaluate treatment group differences in the prevalence of histopathological findings. A two-tailed significance level of 0.05 was selected for all comparisons, and all aforementioned analyses were performed using JMP statistical software (version 8.0.2; SAS Institute, Inc., Cary, NC).
Global gene expression profiling was done using the Genesifter software program (Geospiza) and Ingenuity Pathway Analysis (IPA) software version 8.8 (Ingenuity System). 29 Intensity data were uploaded into the Genesifter software program, robust multiarray analysis normalized, converted to a log 2 scale, screened for homogeneity among samples and treatment groups, and evaluated through a supervised ANOVA and pairwise comparisons. Filter criteria for global profiling included a fold change greater than 2.0, quality greater than 2, and corrected P values of 0.05 using the Benjamini and Hochberg method. Overrepresented pathways or terms related to epithelial cell proliferation, cell cycle progression, and apoptosis were identified using z scores generated in Kyoto Encyclopedia of Genes and Genomes pathway and ontology analyses in Genesifter and other pathway analyses in IPA. An absolute z score of greater than 2.0 in Genesifter was considered significant, whereas a significant overrepresented pathway in IPA was determined using Fisher's exact test with a Benjamini and Hochberg correction. Significant differences in gene number altered by each treatment group compared with the control group were determined using the W 2 test.
RESULTS
Body weights and serum hormone and drug concentrations
Body weights at 6 months posttreatment and serum concentrations of E 1 at 4 and 18 to 24 hours postfeeding were not significantly different between the BZA + CEE and CEE treatment groups (P 9 0.05 for all; Table 1 ). Similarly, plasma concentrations of BZA were not significantly different between the BZA + CEE and BZA treatment groups at 4 and 18 to 24 hours postfeeding (P 9 0.05 for all). Serum E 2 concentrations were significantly lower in the BZA + CEE group relative to the CEE group at 4 hours (P G 0.05) but not at 18 to 24 hours postfeeding. All groups showed a small gain in body weight from baseline to 6 months of treatment, but this increase in body weight reached significance only in the control and BZA groups (P G 0.01 for both).
Breast epithelial proliferation: histomorphometry and Ki67
As depicted in Figure 1 , groups treated with BZA + CEE and BZA had significantly less breast epithelial density relative to the CEE group (P G 0.05 for both) and similar breast epithelial density compared with the control group. Similarly, BZA + CEE and BZA treatment resulted in significantly less immunolabeling for the proliferation marker Ki67 in the terminal ducts than with CEE ( Fig. 2A ; P G 0.05 for all). Ki67 immunolabeling within the lobules showed a similar pattern ( Fig. 2B ; P G 0.05 for BZA and P = 0.08 for BZA + CEE compared with CEE), whereas Ki67 expression within the extralobular ducts was modestly lower in the BZA group compared with the CEE and BZA + CEE groups ( Fig. 2C ; P G 0.05 for both). No significant group differences were seen for Ki67 mRNA expression (see graph A, Supplemental Digital Content 1, http://links.lww.com/MENO/A29).
Breast histopathology
Histopathological findings are summarized in Table 2 . Lobular enlargement was most prevalent in the CEE group, whereas prevalence in the BZA + CEE group was not different from that in the control group (P = 1.0) and significantly less than that observed in the CEE group (P = 0.02). Similarly, the prevalence of lobular enlargement in the BZA group was not significantly different from that in the control group (P = 0.17). Mild columnar cell change was observed in one subject receiving BZA and three subjects receiving CEE. Mild to moderate columnar cell hyperplasia was evident in one breast biopsy among the BZA-treated animals and two breast biopsies among the CEE-treated animals. Atypical ductal hyperplasia was present in one breast biopsy among the BZAalone and CEE-alone-treated animals; however, no lobular enlargement was observed in these cases. No cases of atypical lobular hyperplasia or neoplasia were observed among any breast tissues examined.
ER-> expression and transcriptional activation
Treatment with BZA, CEE, and BZA + CEE altered ER-> immunoreactivity in the breast epithelium but had no sig-nificant effect on ER-> mRNA levels ( Fig. 3A-D) . Groups treated with BZA and BZA + CEE had significantly less ER-> immunolabeling in the terminal ducts and lobules than the control and CEE groups (Fig. 3A, B ; P G 0.0001 for all). In the extralobular ducts, CEE treatment increased ER-> immunolabeling compared with control ( Fig. 3C ; P G 0.05), but this effect was completely blocked by the addition of BZA to CEE (P G 0.05, CEE compared with BZA + CEE; P 9 0.05, BZA + CEE compared with control). Similar to ER-> gene expression, ER-A mRNA expression in the breast was not affected by HT ( Fig. 3E , P = 0.80).
As expected, treatment with CEE significantly increased GREB1 and TFF1 expression compared with control ( Fig. 4A, B ; P G 0.0001 for both). In BZA + CEE cotherapy, BZA inhibited CEE-stimulated GREB1 expression by È5-fold and TFF1 expression by È75-fold compared with treatment with CEE (P G 0.01 for GREB1 and P G 0.0001 for TFF1). Similar to the histology results, treatment with BZA had minimal stimulatory effects on these ER-> activation markers; however, TFF1 expression with BZA and BZA + CEE treatment was slightly higher compared with control (P G 0.05 for both).
Treatment with BZA, CEE, and the combination significantly increased the mRNA expression of PGR relative to control (P G 0.01 for all; see graph B, Supplemental Digital Content 1, http://links.lww.com/MENO/A29). As shown in Figure 4C -E, IHC expression of PGR showed a comparable pattern in which CEE increased PGR expression compared with control in the terminal ducts and lobules as well as in the extralobular ducts (P G 0.01 for all). The protein expression of PGR in the BZA + CEEYtreated group was less than that seen with CEE, but this attenuation did not reach statistical significance in all epithelial regions, and PGR protein expression was significantly induced by BZA + CEE cotherapy in the lobules and extralobular ducts compared with control (P G 0.05). In contrast to PGR mRNA expression, treatment with BZA did not result in a significant increase in PGR protein expression (P 9 0.05 for all breast epithelial regions vs control).
Global transcriptional profiles
Compared with control, treatment with CEE significantly altered a greater number of transcripts than did BZA + CEE and BZA alone (P G 0.0001 by W 2 test for both). For instance, CEE treatment uniquely changed the expression of 36 (named) genes compared with 1 gene altered individually by BZA + CEE and BZA treatment (Fig. 5A, Venn diagram) . These specific genes are provided in the Table, Supplemental Digital Content 2, http://links.lww.com/MENO/A30. The divergent pattern of CEE from BZA + CEE and BZA was also apparent in the global expression analyses as shown in Figure 5B , C. The principal component analysis showed divergent vectors for CEE and BZA + CEE but similar directional profiles for BZA + CEE and BZA (Fig. 5B) . Similarly, the corresponding hierarchical dendrogram clustered BZA + CEE with BZA instead of CEE ( Fig. 5C ), indicating that the transcriptional profile of BZA + CEE more closely resembles BZA than CEE. The heat map for these significantly altered genes identified a large group of genes up-regulated by CEE and antagonized by BZA in BZA + CEE cotherapy but not significantly altered by BZA compared with control ( Fig. 5D ).
Using pattern navigation (ANOVA) and pairwise comparisons at a fold change greater than 2 (adjusted P G 0.05, Benjamini and Hochberg), a complete list of 23 (named) genes antagonized by BZA in BZA + CEE cotherapy was generated. As shown in Table 3 , several of the genes identified were well-known estrogen-driven genes including TFF1, GREB1, IGFBP1, TFF3, IGSF1, STC2, and PPM1K. 40<42 Among these BZA-antagonized genes, no specific pathways related to epithelial cell proliferation or cell cycle progression were identified. On the contrary, a pairwise comparison between BZA + CEE and CEE showed that genes assigned to the ontology terms immune system process and cell death were significantly up-regulated by BZA + CEE (z scores of 4.81 and 3.16, respectively). Notable BZA-agonized genes within these functional categories included major histocompatibility complex class II DP> 1, Granzyme B, Chemokine (C-C motif) ligand 5, and ubiquitin D (see Table, Supplemental Content 3, http://links.lww.com/MENO/A31). However, classic genes related to apoptosis of epithelial cells, including inhibitors (bcl-2, bcl-XL, BAG-1, and mcl-1) and inducers (bax, bad, and bcl-X S ) of cell death, were not significantly regulated by BZA + CEE and BZA therapy in these data sets (data not shown). No significant between-treatment differences or trends toward significance were observed in estrogen metabolizing enzymes (see Table, Supplemental Digital Content 4, http://links.lww.com/MENO/A32).
DISCUSSION
BZA (20 mg/d) is a novel SERM currently being considered as a new menopausal therapy for the treatment of osteoporosis and, in combination with CEE (0.45 mg/d), for menopausal symptoms and the prevention of osteoporosis. 18<20,43<45 Because concern for breast cancer is an impor-tant factor in the decision to initiate HT for many women, 46 here, we investigated the effect of BZA with and without CEE on several biomarkers of cancer promotion in the breast. The addition of BZA to CEE significantly antagonized the stimulatory effects of CEE on total breast epithelial density, lobular size, Ki67 immunolabeling, and specific gene markers of ER-> activity, whereas the treatment effects of BZA alone were comparable with those of control. Similarly, BZA and BZA + CEE had no effect on gene markers of cell proliferation or cell cycle progression, indicating that both treatments lack an estrogen agonist profile in the breast. ER-> protein immunolabeling was significantly lower with BZA and BZA + CEE compared with control and CEE treatments, whereas ER-> mRNA expression was not significantly different, suggesting that increased ER-> protein degradation may contribute to the estrogen inhibitory effects of BZA.
Endogenous estrogens and ERs are well known for their critical role in the development and progression of many breast cancers. Many of the established risk factors of breast cancer (eg, early menarche and late menopause) relate to a lifetime exposure to estrogens, and high levels of endogenous estrogens have been associated with increased breast cancer risk in both premenopausal and postmenopausal women. 47, 48 Estrogens may contribute to breast cancer risk by increasing epithelial cell proliferation and possibly inducing DNA mu-tations through genotoxic metabolites. 49 Many successful strategies for the prevention and treatment of breast cancer have focused on blocking estrogen exposure and actions in the breast. For example, large chemoprevention trials have shown that SERMs such as tamoxifen and raloxifene reduce the incidence of ER-positive breast cancers by 50% to 75% in both high-risk 14, 50 and normal-risk 51 women, whereas aromatase inhibitors, which block estrogen biosynthesis, reduce recurrence and prevent contralateral tumors during adjuvant therapy. 52 Exogenous estrogen therapy in the form of CEE increases mammographic density and benign proliferative lesions in the normal postmenopausal breast, 8, 53, 54 but whether these changes contribute to an increase in breast cancer risk with long-term use is a complex issue and not completely understood. In the Nurses' Health Study, a large prospective US cohort study in which most participating women took CEE at a standard dose of 0.625 mg/day, the relative risk (RR) of ER+/PGR+ breast cancers was not significantly elevated until after 20 years of use (RR, 1.42; 95% CI, 1.13-1.77). 55 Similarly, another US cohort study reported that ET, consisting primarily of CEE (0.625 mg/d), did not significantly increase the RR of breast cancer among normal-weight women until after 15 years of use (RR, 1.6; 95% CI, 1.2-2.2). 9 In the Women's Health Initiative Estrogen-Alone Trial, oral CEE (0.625 mg/d) did not increase the risk of invasive breast cancer over a mean follow-up period of 7.1 years (hazard ratio, 0.80; 95% CI, 0.62-1.04) 8 and resulted in a significant reduction in the incidence of invasive breast cancer among adherent women (hazard ratio, 0.67; 95% CI, 0.47-0.97; P = 0.03), 8 which continued for at least 4 years beyond the end of the study. 56 The biological mechanisms related to these effects are currently unclear.
In the current study, BZA fully inhibited the estrogenic effects of CEE on total breast epithelial density, lobular size, and Ki67 protein expression in the terminal ductal epithelium while having neutral effects when administered alone. These results support a small body of previous evidence from cell culture, preclinical, and clinical studies demonstrating that BZA is an estrogen antagonist in the breast. 23,57<60 Results from in vitro studies showed that BZA did not stimulate proliferation of ER->Ypositive human breast cancer cells when given alone and antagonized proliferation when given with E 2 . 57 Similarly, a study in an ovariectomized sexually immature mouse model found that the addition of BZA to CEE completely blocked CEE actions on mammary ductal growth and a specific gene marker of ER-> activity, whereas the treatment effects of BZA alone were comparable with those of vehicle. 59 A randomized (phase III) clinical trial investigating the treatment effects of various BZA doses in osteoporotic postmenopausal women reported that BZA 20 mg did not significantly alter mammographic density after 24 months of treatment compared with baseline. 60 Safety data from this trial revealed no significant difference in breast cancer incidence or other breast-related adverse events (breast pain, breast cyst, and fibrocystic breast disease) between the BZA and placebo groups, which persisted for an additional 3 years. 61 Mammographic density and breast safety data for the BZA 20 mg + CEE 0.45 mg combination have been reported only after 24 months of treatment in a randomized, phase III clinical trial consisting of 3,397 osteoporotic postmenopausal women (SMART-1), and the findings were similar to the results for BZA 20 mg alone. 23 Although data from previous reports and the present study have shown that BZA is an estrogen antagonist in the breast, the inhibitory effects of BZA on ER activity are highly dependent on the BZA/estrogen dose ratio and, possibly, the type of estrogen used in the BZA + estrogen regimen. In human breast cancer cell culture studies, a BZA dose of 10 nM completely antagonized the proliferative effects of coadministered E 2 , but a smaller BZA dose of 1.0 pM resulted in negligible inhibition. 57 This dose-dependent effect is also apparent in other estrogen-sensitive tissue such as the endometrium. For instance, in the 24-month SMART-1 trial, the uterotropic effects of CEE (0.45 or 0.625 mg/d) on the occurrence of endometrial hyperplasia were effectively antagonized with 20 but not 10 mg/day of BZA. 21 Thus far, the effects of BZA on the normal postmenopausal breast have been evaluated only with oral CEE as the primary estrogen therapy, 23 and it is not known whether BZA 20 mg would provide protective effects in the breast and endometrium if coadministered with standard doses of oral or transdermal E 2 . Based on evidence from studies of oral estrogen effects in macaques, a standard dose of CEE may have a lesser stimulatory effect on breast epithelial proliferation than a standard 1.0 mg/day dose of E 2 , 62 suggesting that the dose of BZA needed for complete antagonism may vary with type of ET.
In the current study, ER-> protein levels in lobular and terminal ductal epithelium were significantly lower with BZA and BZA + CEE compared with control and CEE treatments, whereas ER-> mRNA levels remained unchanged. This unexpected finding suggests that BZA may increase degradation of ER-> posttranslationally. Proteolysis of ER-> in breast epithelial cells has been shown to be mediated by the ubiquitinproteasome pathway, 63 and it is possible that BZA binding to the ER-> may facilitate ubiquitation and proteasome-mediated degradation. This idea is supported by a recent in vitro study that showed proteasome-mediated degradation of the ER-> by BZA (without the coadministration of one or more estrogens) in hormone-resistant breast cancer cells. 64 In this study, MCF-7:5C cells were treated with a proteasome inhibitor, which completely blocked ER-> degradation by BZA, whereas treatment with a protein synthesis inhibitor had minimal effects on BZA-induced ER-> protein degradation. 64 Collectively, these data support the idea that ER-> degradation may contribute to the estrogen antagonist effects of BZA in the breast.
Other notable findings in this study are as follows: (1) the antagonism of Ki67 immunoexpression in the terminal ducts by BZA + CEE treatment compared with CEE; (2) the induction of PGR expression by BZA with and without CEE; and (3) the up-regulation of genes related to immune-mediated apoptosis, specifically cytotoxic T lymphocyteYmediated apoptosis, by BZA + CEE compared with CEE treatment. The terminal ducts are part of the terminal ductal lobular units of the breast, which is the epithelial unit at the end of an arborizing network of (extralobular) ducts. Marked inhibition of Ki67 expression in this region by BZA + CEE is of clinical importance considering that this is the site from which many breast cancers originate. 38 The biological significance of the increased mRNA expression of PGR with BZA and BZA + CEE therapy is not known; however, increased levels of PGR protein have been reported previously in the breast of postmenopausal macaques treated with tamoxifen. 26 Equally of interest is the finding that the addition of BZA to CEE significantly up-regulated the expression of genes related to cytotoxic T lymphocyteYmediated apoptosis, particularly Granzyme B. Previous in vitro studies have shown that E 2 increases breast cancer cell survival by inducing the expression of a Granzyme B inhibitor in these cells (proteinase inhibitor 9), and treatment with a SERM (tamoxifen) antagonizes these effects. 65 Whether BZA has a similar role in the normal postmenopausal breast is not known. Qualitative assessments of the breast biopsy tissues revealed mild lobular lymphocytic infiltration in approximately 40% of the samples, with no betweengroup differences.
The strengths of this study include the randomized, placebocontrolled study design, inclusion of a CEE-alone study group, and the ability to control diet, dose, and other environmental variables. The phase III human clinical trials investigating BZA alone and BZA + CEE did not have a CEE-alone group because all participating women did not have a previous hysterectomy. 18, 19 In addition, these trials were designed to measure changes in bone mineral density as the primary endpoint among osteoporotic women and not changes in mammographic density or breast cancer incidence. 18, 19 Breast assessments among these trials were retrospective analyses and therefore may have been subject to selection bias. 23, 60, 61 Notable in the same regard, participants in a BZA versus placebo trial who had previously taken HT (98 wk before the study) were included in the mammogram analyses. 60 A potential weakness of the current macaque study is the lack of individual dosing. Because of the large size of the study, hormone therapies were administered in the diet and animals were fed in social groups.
CONCLUSIONS
In this preclinical trial, BZA antagonized the proliferative and transcriptional effects of CEE in the normal postmenopausal nonhuman primate breast, whereas BZA had neutral effects. ER-> protein levels were significantly lower with BZA and BZA + CEE treatment compared with control and CEE, suggesting that BZA may promote ER-> protein degradation in addition to blocking the binding of estrogens. These findings support the idea that BZA may be a safe alternative to the progestin component in combined HT for symptomatic postmenopausal women.
